Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
January 18 2024 - 4:05PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is saddened to
announce the passing of its former President, Srdjan (Serge)
Stankovic M.D., M.S.P.H. Serge passed away peacefully on December
29, 2023, following a prolonged illness.
“Serge” as he was known to friends and colleagues, joined Acadia
in 2015 and led Acadia’s Research and Development organization for
more than seven years. He played an instrumental role in Acadia
becoming a commercial stage company, providing his significant drug
development expertise to the approval and launch of NUPLAZID®
(pimavanserin) for the treatment of Parkinson’s disease psychosis
and to the approval of Acadia’s second drug to the market, DAYBUE™
(trofinetide) for the treatment of Rett syndrome. Serge served on
Acadia’s executive management team and led all research and
development efforts until he retired from his role as President at
the end of 2022.
“This is a moment of profound sadness for those of us who knew
Serge. His contributions have left an indelible impact on Acadia,
patients and caregivers who will continue to benefit from his work
and legacy for decades to come,” said Steve Davis, Acadia’s Chief
Executive Officer. “Serge was my dear friend and a frequent
sounding board and will be remembered for his intellectual
curiosity, sense of humor and passion for science. We mourn his
loss and extend our deepest condolences to his wife Ana, his
daughter Sandra and Serge’s extended family.”
Serge was born in Yugoslavia and received his degree in medicine
from the University of Belgrade. He completed his residency in
psychiatry there and served as an attending psychiatrist and
clinical physician. After emigrating to the U.S., he received his
Master of Science in Public Health from the University of Alabama
at Birmingham, where he joined the Department of Psychiatry as a
research fellow and instructor in Clinical Psychopharmacology.
Serge transitioned to the private sector as a medical officer at
UCB Pharma and quickly rose through the organization to Vice
President of U.S. Clinical Development. He went on to hold
leadership positions in research and development at Johnson &
Johnson, Neurogen Pharmaceuticals, Forest Laboratories, Teva
Pharmaceuticals, and Alkermes.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only FDA-approved
drug to treat hallucinations and delusions associated with
Parkinson’s disease psychosis and the first and only FDA-approved
drug for the treatment of Rett syndrome. Our clinical-stage
development efforts are focused on treating the negative symptoms
of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease
psychosis and multiple other programs targeting neuropsychiatric
symptoms in central nervous system disorders. For more information,
visit us at www.acadia.com and follow us on LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117445781/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858)
261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2024 to May 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From May 2023 to May 2024